Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone

J Clin Oncol. 2012 Jul 10;30(20):e175-9. doi: 10.1200/JCO.2011.41.1413. Epub 2012 Jun 11.
No abstract available

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bone Neoplasms / drug therapy
  • Bone Neoplasms / secondary
  • Boronic Acids / administration & dosage
  • Bortezomib
  • Cyclophosphamide / administration & dosage
  • Dexamethasone / administration & dosage
  • Drug Administration Schedule
  • Female
  • Humans
  • Lenalidomide
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / secondary*
  • Middle Aged
  • Multimodal Imaging
  • Multiple Myeloma / drug therapy*
  • Positron-Emission Tomography
  • Pyrazines / administration & dosage
  • Recurrence
  • Thalidomide / administration & dosage
  • Thalidomide / analogs & derivatives
  • Tomography, X-Ray Computed
  • Treatment Failure

Substances

  • Boronic Acids
  • Pyrazines
  • Thalidomide
  • Bortezomib
  • Dexamethasone
  • Cyclophosphamide
  • Lenalidomide